Published in Cancer Weekly, August 27th, 2002
Amgen revolutionized anemia treatment with the discovery of recombinant human erythropoietin in 1984, which led to the development of Epoetin alfa, currently marketed as EPOGEN and Procrit. Building on this heritage, Amgen created Aranesp, which was developed to simplify anemia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.